Urinary incontinence associated with pharmacological treatment of Chronic Obstructive Lung Disease: An integrative review
DOI:
https://doi.org/10.33448/rsd-v10i9.17558Keywords:
Urinary Incontinence; Pharmacological treatment; Chronic obstructive pulmonary disease.Abstract
Chronic Obstructive Pulmonary Disease (COPD) is a lung disease, often associated with smoking. COPD patients have persistent, including urinary incontinence. Therefore, a research has the general objective of knowing the physiological mechanism of urinary incontinence associated with the pharmacological treatment of COPD. As a methodological process, this study is an integrative review that included randomized clinical trials, quasi-experimental intervention studies, cohort and case-control. The selection of studies was carried out in the databases PubMed, SciELO, Science Direct and BVS (Virtual Health Library), published between 2010 and July 2020, in Portuguese and English. Pharmacological classes SABA, LABA, SAMA, LAMA, ICS and iPDE4 were considered to investigate adverse effects and check for the presence of urinary symptoms caused by these drugs. In the results and discussion, 113 articles were identified with the investigated descriptors. After the article selection process, 14 studies resulted: PubMED (13); and Science Direct (1). The pharmacological class related to urinary incontinence identified in this study was that of anticholinergics / antimuscarinics. From this perspective, it can be considered that Urinary Incontinence has a low relationship with the adverse effects of drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD). However, as urinary incontinence is not considered a life-threatening problem, it is possible that it has not been included among the adverse events to be explored.
References
Aigon, A. & Billecocq, S. (2018). Prevalência e impacto na qualidade de vida da incontinência urinária em uma população adulta com doenças pulmonares obstrutivas crônicas, revisão da literatura. Prog Urol. 28 (17), 962 -72.
Alexander, L. et al. (2015). Gestão da incontinência urinária em mulheres idosas frágeis. Obstetrícia, Ginecologia e Medicina Reprodutiva. 25 (3), 75-82.
Agusti, A., Fabbri, L. M. & Singh, D. et al. (2018). Corticosteróides inalados em COPD: amigo ou inimigo? Eur Respir J. 52, 1801219.
Barbosa, A. T. F. et al. (2017). Fatores associados à Doença Pulmonar Obstrutiva Crônica em idosos. Ciência & Saúde Coletiva, 22, 63-73.
Battaglia, S., Benfante, A., Principe, S., Basile, L. & Scichilone, N. (2019). Urinary Incontinence in Chronic Obstructive Pulmonary Disease: A Common Co-morbidity or a Typical Adverse Effect? Drugs Aging., 36(9):799-806.
Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. (2010). Departamento de Atenção Básica. Doenças respiratórias crônicas / Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Básica. – Brasília: Ministério da Saúde.
Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. (2013). Departamento de Atenção Básica. Diretrizes para o cuidado das pessoas com doenças crônicas nas redes de atenção à saúde e nas linhas de cuidado prioritárias / Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Básica. – Brasília: Ministério da Saúde.
Burge, A. T., Lee, A. L., Kein, C., Buttton, B. M., Sherburn, M. S. & Miller, B. (2017). Prevalence and impact of urinary incontinence in men with chronic obstructive pulmonary disease: a questionnaire survey. Physiotherapy., 103(1):53-58.
Dale, P. R. et al. (2014). The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease. Current opinion in pharmacology, v. 16, p. 31-42.
De Oca, M. M., Varela, M. V. L. & Acuña, A. (2020). Asociación Latinoamericana de Tórax - ALAT. Guia de Práctica Clínica Latinoamericana de EPOC (LatinEPOC-2019). Revista Educativa de ALAT.
D'urzo, A., Rennard, S., Kerwin, E., Donohue, J.F., Lei, A., Molins, E. & Leselbaum, A. (2017). A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respir Med., 125:39-48.
D’urzo, A. D., Rennard, S. I., Kerwin, E. M., Mergel, V., Leselbaum, A. R. & Caracta, C. F. et al. (2014). Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res., 15:123.
Fernandes, F. L. A., Cukier, A., Camelier, A. A., Fritscher, C. C., Costa, C. H. D., Pereira, E. D. B. & Jardim, J. R. (2017). Recomendações para o tratamento farmacológico da DPOC: perguntas e respostas. Jornal Brasileiro de Pneumologia, 43(4), 290-301.
Gonçalves-Macedo, L. et al. (2019). Tendências da morbidade e mortalidade da DPOC no Brasil, de 2000 a 2016. Jornal Brasileiro de Pneumologia, 45, e20180402-e20180402.
Hashimoto, M., Hashimoto, K., Ando, F., Kimura, Y., Nagase, K. & Arai, K. (2015). Prescription rate of medications potentially contributing to lower urinary tract symptoms and detection of adverse reactions by prescription sequence symmetry analysis. J Pharm Health Care Sci, 1:7.
Janson, C. (2020). Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease. J Thorac Dis.,12(4):1561-1569.
Laforce, C., Derom, E., Bothner, U., Kloer, I.M., Trampisch, M. & Buhl, R. (2018). Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate- to-very severe COPD and renal impairment in the TONADO® studies. Int J Chron Obstruct Pulmon Dis., 1, 13:1819-1831.
Loke, Y. K. & Singh, S. (2013). Risk of acute urinary retention associated with inhaled anticholinergics in patients with chronic obstructive lung disease: systematic review. Therapeutic Advances in Drug Safety (Reino Unido) 4 [1].
Lipson, D. A., Barnacle, H., Birk, R., Brealey, N., Locantore, N. & Lomas, D. A. et al. (2017). FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 196:438–46.
Lipson, D. A., Barnhart, F., Brealey, N., Brooks, J., Criner, G. J. & Day, N. C. et al. (2018). Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med., 378:1671–80.
Martinez, F. J., Calverley, P. M., Goehring, U. M., Brose, M., Fabbri, L. M. & Rabe, K. F. (2015). Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet., 385:857–66.
Martinez, F. J., Rabe, K. F., Sethi, S., Pizzichini, E., Mcivor, A. & Anzueto, A. et al. (2016). Effect of roflumilast and inhaled corticosteroid/longacting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. Am J Respir Crit Care Med., 194:559–67.
Mendes, K. D. S., Silveira, R. C. C. P. & Galvão, C. M. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto enfermagem, 17, 758-764.
Nascimento, O. A., Camelier, A., Rosa, F. W., Pérez-Padilla, R. & Jardim, J. R. (2007). A Doença Pulmonar Obstrutiva Crônica é subdiagnosticada e subtratada em São Paulo (Brasil): resultados do estudo PLATINO. Braz J Med Biol Res, 40 (7): 887-95.
Malta, D. C., Stopa, S. R., Szwarcwald, C. L., Gomes, N. L., Silva Júnior, J. B. & Reis, A. A. C. (2015). A estatísticas e o monitoramento das principais doenças crônicas não transmissíveis no Brasil - Pesquisa Nacional de Saúde, 2013. Rev Bras Epidemiol, 18 (supl. 2): 3-16.
Menezes, A. M. B. et al. (2011). Tratamento farmacológico da DPOC. Jornal Brasileiro de Pneumologia, 37, 527-543.
Moreira, G. L. et al. (2014). PLATINO, estudo de seguimento de nove anos sobre DPOC na cidade de São Paulo: o problema do subdiagnóstico. Jornal Brasileiro de Pneumologia, 40, 30-37.
Negewo, N. A., Gibson, P. G. & Mcdonald, V. M. (2015). COPD and its comorbidities: Impact, measurement and mechanisms. Respirology, 20(8):1160-71.
OMS. Organização Mundial da Saúde. (2008). Vigilância global, prevenção e controle das doenças respiratórias crônicas: Uma abordagem integradora. Lisboa: Organização Mundial da Saúde.
Papi, A., Vestbo, J., Fabbri, L., Corradi, M., Prunier, H. & Cohuet, G. et al. (2018). Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet., 391:1076–84.
Silva, C. C., Santana, J. R., Silva, V. O., Januário, P. G., Oliveira, H. F. &Camelier, A. A. et al. (2019). A perda urinária é frequente em pacientes com Doença Pulmonar Obstrutiva Crônica (DPOC) atendidos ambulatorialmente. Rev Pesqui Fisioter., 9(3):378-385.
Sousa, L. A. O. de et al. (2018). Prevalência e características dos eventos adversos a medicamentos no Brasil. Cadernos de Saúde Pública, 34, e00040017, 2018.
Souza, T. T., Godoy, R. R., Rotta, I., Pontarolo, R., Fernandez-Llimos, F. & Correr, C. J. (2014). Morbidade e mortalidade relacionadas a medicamentos no Brasil: revisão sistemática de estudos observacionais. Rev Ciênc Farm Básica Apl, 35:519-32.
Souza, M. T., Silva, M. D. & Carvalho, R. (2010). Revisão integrativa: o que é e como fazer. Einstein (São Paulo), 8, 102-106.
Singh, D., Jones, P. W., Bateman, E. D., Korn, S., Serra, C. & Molins, E. et al. (2014). Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med., 14:178.
Stephenson, A., Seitz, D. & Bell, C. M. et al. (2011). Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med,171(10):914–920.
Tashkin, D. P., Celli, B. & Senn, S. et al. (2008). A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 359(15): 1543-54.
Vespasiani-Gentilucci, U. et al. (2018). The pharmacological treatment of chronic comorbidities in COPD: mind the gap!. Pulmonary Pharmacology & Therapeutics, 51, 48-58.
Zheng, J., De Guia, T., Wang-Jairaj, J., Newlands, A. H., Wang, C., Crim, C. & Zhong, N. (2015). Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg, 100/25 mcg, 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Curr Med Res Opin., 31(6):1191-200.
Zuwallack, R., Allen, L., Hernandez, G., Ting, N. & Abrahams, R. (2014). Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis., 9:1133-1144.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Phydel Palmeira Carvalho; Roberto Bandeira Tosta Maciel; Gabriel Couto Rocha; Murilo de Jesus Porto; Juliana Santana Montalvão Galliza; Karla Ramos Melo Oliveira; Aquiles Assunção Camelier; Rosa Malena Fagundes Xavier; Fernanda Warken Rosa Camelier
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
